Evidence map›Paper›PMID 39639328›Full record

ArticleJournal of translational medicine2024

A CT-based subregional radiomics nomogram for predicting local recurrence-free survival in esophageal squamous cell cancer patients treated by definitive chemoradiotherapy: a multicenter study.

Jie Gong, Jianchao Lu, Wencheng Zhang, Wei Huang, Jie Li, Zhi Yang, Fan Meng, Hongfei Sun, Lina Zhao

Abstract readMulticenter Study
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jie Gong *Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, 127 West Changle Road, Xi'an, China.
Jianchao Lu *Department of Radiation Oncology, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institution, University of Electronic Science and Technology of China, Chengdu, China.
Wencheng Zhang *Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Wei Huang *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.
Jie LiDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, 127 West Changle Road, Xi'an, China.
Zhi YangDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, 127 West Changle Road, Xi'an, China.
Fan MengDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, 127 West Changle Road, Xi'an, China.
Hongfei SunDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, 127 West Changle Road, Xi'an, China.
Lina ZhaoDepartment of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, 127 West Changle Road, Xi'an, China. zhaolina@fmmu.edu.cn.ORCID 0000-0002-0011-6471

Funding

National Natural Science Foundation of China 82272941Xi'an Science and technology plan project 24YXYJ0160Xijing Hospital Research Project XJZT24QN04
6 · The paper itself

Abstract

backgroundTo develop and validate an online individualized model for predicting local recurrence-free survival (LRFS) in esophageal squamous cell carcinoma (ESCC) treated by definitive chemoradiotherapy (dCRT).

methodsESCC patients from three hospitals were randomly stratified into the training set (715) and the internal testing set (179), and patients from the other hospital as the external testing set (120). The important radiomic features extracted from contrast-enhanced computed tomography (CECT)-based subregions clustered from the whole volume of tumor and peritumor were selected and used to construct the subregion-based radiomic signature by using COX proportional hazards model, which was compared with the tumor-based radiomic signature. The clinical model and the radiomics model combing the clinical factors and the radiomic signature were further constructed and compared, which were validated in two testing sets.

resultsThe subresion-based radiomic signature showed better prognostic performance than the tumor-based radiomic signature (training: 0.642 vs. 0.621, internal testing: 0.657 vs. 0.638, external testing: 0.636 vs. 0.612). Although the tumor-based radiomic signature, the subregion-based radiomic signature, the tumor-based radiomics model, and the subregion-based radiomics model had better performance compared to the clinical model, only the subregion-based radiomics model showed a significant advantage (p < 0.05; training: 0.666 vs. 0.616, internal testing: 0.689 vs. 0.649, external testing: 0.642 vs. 0.604). The clinical model and the subregion-based radiomics model were visualized as the nomograms, which are available online and could interactively calculate LRFS probability.

conclusionsWe established and validated a CECT-based online radiomics nomogram for predicting LRFS in ESCC received dCRT, which outperformed the clinical model and might serve as a powerful tool to facilitate individualized treatment.

trial registrationThis retrospective study was approved by the ethics committee (KY20222145-C-1).

Indexed as

ChemoradiotherapyEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaNeoplasm Recurrence, LocalNomogramsTomography, X-Ray ComputedAgedCarcinoma, Squamous CellDisease-Free SurvivalFemaleHumansMaleMiddle AgedPrognosisProportional Hazards ModelsRadiomicsDefinitive chemoradiotherapyEsophageal squamous cell cancerLocal recurrence-free survivalRadiomicsSubregion

Identifiers

PMID39639328
PMCPMC11619118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.